Corporation
Aurora Cannabis Inc.
- Meetings this Parliament
- 13
- With MPs
- 5
- Since Nov 2021
- 56
- Active registrations
- 1
Most recent reported meeting: Feb 26, 2026.
Lobbying by Aurora Cannabis Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Jun 29, 2026
Filed by Miguel Martin, CEO
Lobbyists
- Aaron Denhartog · Manager, Government Relations
- Miguel Martin · CEO
Institutions they may lobby: Canada Revenue Agency (CRA), Finance Canada (FIN), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Veterans Affairs Canada (VAC)
What they're lobbying on (5)Hide details
- Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
- Regulations affiliated with Bill C- 45 regarding the legalization of cannabis. Formerly known as Bill C-45: An Act Respecting Cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts.
- Formerly known as Bill C-45: An Act Respecting Cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts. Cannabis Act SC 2018 S16
- Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations.
- Canada's policy regarding the rules governing the legalization of marijuana
Registration 947021-360412-32. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Miguel Martin · In-house (corporation)
- Karina Gould · Leader of the Government in the House of Commons
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Jane Hicks · Director General, VAC, Veterans Affairs Canada (VAC)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Varun Srivatsan · Deputy Director of Policy, Finance Canada (FIN)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Michael Hamm · Director of Policy, Veterans Affairs Canada (VAC)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- John Clare · Director General, Health Canada (HC)
- David Pellman · Director General, Health Canada (HC)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Jean-Denis Garon · Member of Parliament
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Marie-Hélène Gaudreau · Member of Parliament, Health Canada (HC)
- Blake Richards · Member of Parliament
Regulations affiliated with Bill C- 45 regarding the legalization of cannabis. Formerly known as Bill C-45: An Act Respecting Cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts. Read more
-
Reported by Miguel Martin · In-house (corporation)
- Adam Chambers · Member of Parliament
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Cathay Wagantall · Member of Parliament, House of Commons
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Patrick Weiler · Member of Parliament
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Jane Hicks · Director General, VAC, Veterans Affairs Canada (VAC)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Steven Harris · Assistant Deputy Minister, Veterans Affairs Canada (VAC)
Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations. Read more
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
-
Reported by Miguel Martin · In-house (corporation)
- Doug Ford · Premier of Ontario, House of Commons
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs Read more
Canada's policy regarding the rules governing the legalization of marijuana
-
Reported by Miguel Martin · In-house (corporation)
- Patrick Weiler · Member of Parliament
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
Taxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- daniel Riri · Analyst/Economist, Finance Canada (FIN)
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Yves Le Moullec · Manager, Innovation, Science and Economic Development Canada (ISED)
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Eric Costen · Associate Deputy Minister, Health Canada (HC)
- Kendal Weber · Assistant Deputy Minister, Health Canada (HC)
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Darren Weiner · Directeur, Canada Revenue Agency (CRA)
- Jason Sterling · Senior Rulings Office, Canada Revenue Agency (CRA)
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Scot Davidson · Member of Parliament
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Adam Chambers · Member of Parliament
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Blake Richards · Member of Parliament
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Gervais Coulombe · Senior Director, Excise Taxation and Legislation, Finance Canada (FIN)
- Jack Glick · Senior Advisor, Finance Canada (FIN)
Taxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Leslyn Lewis · Member of Parliament
HealthTaxation and Finance
-
Reported by Miguel Martin · In-house (corporation)
- Jed Graham · Policy Advisor, Health Canada (HC)
HealthTaxation and Finance
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.